Compare Abeona Therapeutics Inc (ABEO) vs Carparts.Com Inc (PRTS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Carparts.Com Inc — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Carparts.Com Inc trades at $6 (market cap $49.97M). The key difference: Abeona Therapeutics Inc is far larger — about 7.5× Carparts.Com Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Carparts.Com Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | PRTS | |
|---|---|---|
Market Cap | $373.32M | $49.97M |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $11.40 |
52-Week Low | $4.17 | $3.88 |
Enterprise Value | $228.22M | $64.94M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
CarParts.com (PRTS) trades at $6.14, down 0.65% on the day, following a recent 10:1 reverse stock split that helped it regain Nasdaq compliance. The stock shows a bearish technical signal with negative cash flow and net losses, though it has beaten earnings estimates for three consecutive quarters. Recent developments include a new $25 million credit facility and the launch of a co-branded Mastercard, signaling efforts to stabilize operations and enhance customer financing options.
Despite persistent losses and negative cash flow, PRTS maintains a low P/S ratio of 0.07 and has analyst support with 60% buy ratings. The primary risk is sustained profitability challenges amid declining revenue, but cost discipline and new financial tools may provide a path to recovery if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →
